Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency
This investigation, conducted under real life conditions, unveils a notable pharmacovigilance safety signal associating SRI usage with hypertension reporting. No dose-response effect was detectable. Further longitudinal studies are warranted.
Authors
- Basile Chrétien (ORCID: https://orcid.org/0000-0002-7483-2489)
- Sophie Fédrizzi
- Kazuki Nishida (ORCID: https://orcid.org/0000-0003-0367-8557)
- Xavier Humbert (ORCID: https://orcid.org/0000-0003-2747-9229)
- Marion Sassier
- Andry Rabiaza
- Charles Dolladille (ORCID: https://orcid.org/0000-0003-0449-6261)
- Joachim Alexandre (ORCID: https://orcid.org/0000-0002-9197-8404)
Institutions
- Inserm (FR)
- Normandie Université (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Nagoya University (JP)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1371/journal.pone.0317841
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00